前交叉韧带重建联合骨-髌腱-骨自体移植术后疼痛与阿片类药物使用:收肌管阻滞联合IPACK阻滞与单纯收肌管阻滞的单中心随机对照试验
该单中心随机对照试验纳入102例使用骨-髌腱-骨自体移植行前交叉韧带重建的患者,比较收肌管阻滞(ACB)联合IPACK阻滞与单纯ACB的术后疼痛、满意度和阿片类药物需求。最终分析96例,IPACK组在术后第1、2、3天阿片类药物用量显著低于ACB组,术后第1天和3天疼痛评分显著更低,术后第1天满意度更高。结论提示,在ACB基础上加用IPACK阻滞可减少ACB术后急性期阿片类药物消耗、改善疼痛控制并提高满意度。
要点
- IPACK组术后第1天阿片用量平均6.1 MME显著低于ACB组10.7 MME(P<.001)。
- IPACK组术后第1天疼痛评分67.7显著低于ACB组55.2(P=.024)。
- IPACK组术后第1天满意度平均7.3显著高于ACB组5.6(P=.001)。
核心结论
- 研究结果提示,在ACB基础上加用IPACK阻滞可减少骨-髌腱-骨自体移植前交叉韧带重建术后急性期阿片类药物消耗、改善疼痛控制并提高疼痛控制满意度。
研究设计与样本
- 单中心随机对照试验,证据等级2级,共招募102例使用骨-髌腱-骨自体移植行前交叉韧带重建的患者,随机分为单纯ACB组和ACB联合IPACK阻滞组,最终分析96例(ACB组47例,IPACK组49例)。
- 术后24小时(术后第1天)、48小时(术后第2天)、72小时(术后第3天)和1周随访评估疼痛评分、阿片类药物消耗和满意度;连续变量采用t检验或非参数检验,分类变量采用卡方检验;阿片类药物用量以吗啡毫克当量(MME)报告。
主要发现
- IPACK组术后第1天阿片用量平均6.1(IQR 4.5-7.7)MME vs ACB组10.7(IQR 8.6-13.0)MME(P<.001);术后第2天7.3(IQR 5.2-9.5)MME vs 12.5(IQR 10.0-15.0)MME(P=.001);术后第3天4.2(IQR 2.8-5.5)MME vs 9.4(IQR 7.1-12.0)MME(P<.001)。
- IPACK组术后第1天视觉模拟量表疼痛评分平均67.7(IQR 62.0-73.0)vs ACB组55.2(IQR 48.0-63.0)(P=.024);术后第3天54.9(IQR 48.0-63.0)vs 44.4(IQR 37.0-51.0)(P=.037)。
- IPACK组术后第1天满意度平均7.3(IQR 6.6-8.0)vs ACB组5.6(IQR 4.8-6.4)(P=.001);术后第7天两组间未观察到统计学显著差异。
- 回归分析显示,IPACK阻滞(β=-13.0;P=.03)和男性(β=-9.9;P=.024)是术后第1天阿片类药物使用的显著负向预测因素;IPACK组阿片用量减少的关联在术后第2天(β=-12.0;P=.019)和术后第3天(β=-15.0;P<.001)持续存在。
- 两组在年龄、体重指数和性别方面无统计学显著差异(P>.05);队列中男性占60.4%,平均年龄28.40±7.51岁(范围18-55岁),平均体重指数25.67±4.84 kg/m²。
临床怎么用
- 原文结论认为,在ACB基础上加用IPACK阻滞可减少骨-髌腱-骨自体移植前交叉韧带重建术后急性期阿片类药物消耗、改善疼痛控制并提高疼痛控制满意度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efforts to decrease pain, improve early rehabilitation, and reduce opioid consumption have prompted a focus on peripheral nerve blocks for pain management after anterior cruciate ligament reconstruction (ACLR). The commonly used adductor canal block (ACB) might not provide sufficient postoperative pain control because of its lack of coverage of the posterior aspect of the knee. The addition of the IPACK (interspace between the popliteal artery and the capsule of the posterior knee) block, which targets this area, to the standard ACB could potentially provide better pain control after ACLR over the current standard of care. PURPOSE/HYPOTHESIS: The purpose of this study was to compare and analyze postoperative pain, satisfaction, and opioid demand between the standard ACB and a combination of an ACB and IPACK block in patients undergoing ACLR with a bone-patellar tendon-bone (BTB) autograft. It was hypothesized was that the addition of the IPACK block would substantially improve early postoperative pain control and minimize opioid use. STUDY DESIGN: Randomized controlled trial; Level of evidence, 2. METHODS: A total of 102 patients undergoing ACLR with a BTB autograft at a single institution were recruited. Patients were randomly assigned to receive either the ACB alone or the ACB plus IPACK block. Patients were contacted at 24 hours (postoperative day [POD] 1), 48 hours (POD 2), 72 hours (POD 3), and 1 week to assess postoperative pain scores, opioid consumption, and satisfaction with their postoperative pain control. Intergroup comparative analysis was performed using a t test or nonparametric test for continuous variables and the chi-square test for categorical variables. Opioid usage was reported as morphine milligram equivalents (MME). RESULTS: The final analysis included 96 patients, with 47 in the control group (ACB) who received only the ACB and 49 in the experimental group (IPACK) who received the ACB and an additional IPACK block. The cohort was composed of 60.4% male patients with a mean age of 28.40 ± 7.51 years (range, 18-55 years) and a mean body mass index of 25.67 ± 4.84 kg/m2. There were no statistically significant differences between the groups with respect to age, body mass index, or sex (P > .05). Patients in the IPACK group reported significantly lower opioid usage than those in the ACB group on POD 1 (mean, 6.1 [interquartile range (IQR), 4.5-7.7] vs 10.7 [IQR, 8.6-13.0] MME, respectively; P < .001), POD 2 (mean, 7.3 [IQR, 5.2-9.5] vs 12.5 [IQR, 10.0-15.0] MME, respectively; P = .001), and POD 3 (mean, 4.2 [IQR, 2.8-5.5] vs 9.4 [IQR, 7.1-12.0] MME, respectively; P < .001). The visual analog scale for pain score on POD 1 (mean, 67.7 [IQR, 62.0-73.0] vs 55.2 [IQR, 48.0-63.0], respectively; P = .024) and POD 3 (mean, 54.9 [IQR, 48.0-63.0] vs 44.4 [IQR, 37.0-51.0], respectively; P = .037) was statistically higher in the ACB group compared with the IPACK group. On POD 1, patient satisfaction was higher in the IPACK group than in the ACB group (mean, 7.3 [IQR, 6.6-8.0] vs 5.6 [IQR, 4.8-6.4], respectively; P = .001). No statistically significant differences were observed between groups on POD 7. On regression analysis, IPACK block (β = -13.0; P = .03) and male sex (β = -9.9; P = .024) were significant negative predictors for opioid use on POD 1. The association of reduced opioid use in the IPACK group persisted on POD 2 (β = -12.0; P = .019) and POD 3 (β = -15.0; P < .001). CONCLUSION: The results of this study suggest that the addition of an IPACK block to an ACB leads to reduced opioid consumption, improved pain control, and higher satisfaction with pain control acutely after ACLR with a BTB autograft. REGISTRATION: NCT05286307 (ClinicalTrials.gov).
引用
- Rao N, Triana J, Avila A, et al. Postoperative Pain and Opioid Usage With Combined Adductor Canal and IPACK Block Versus Isolated Adductor Canal Block After Anterior Cruciate Ligament Reconstruction With a Bone-Patellar Tendon-Bone Autograft: A Single-Center Randomized Controlled Trial. Am J Sports Med. 2025. PMID: 40308075. doi:10.1177/03635465251328609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。